Board recommends Dividend
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 21, 2012, inter alia, has recommended a dividend @ 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2012 subject to approval of the same by shareholders at the Annual General Meeting. Board to consider Dividend
Venus Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on June 21, 2012, inter alia, to consider and approve the following:1. Annual Accounts of the Company for the year ended March 31, 2012.2. Recommendation of dividend for the year 2011-2012.3. Fix the Date of Annual General Meeting. Venus drug to fight resistant 'superbugs' wins US Patent
Venus Remedies Ltd has informed BSE that the Company has received patent from the US Patent Office for a breakthrough antibiotic product.Announcement:"Venus Remedies Ltd has received patent from US Patent Office for a breakthrough antibiotic product."(For more details kindly refer Corporate Announcements on www.bseindia.com). Venus Remedies bags another patent grant from South Africa
Venus Remedies Ltd has informed BSE regarding "Venus Remedies bags another patent grant from South Africa".Announcement:"Venus Remedies Limited has received its first patent for a novel antibiotic combination of carbapenem and aminoglycoside. Pioneering into antibacterial portfolio, Venus has added another international patent from CIPRO (companies and Intellectual Property Registration Office) South Africa to its basket for the antibiotic... Financial Results & Limited Review for March 31, 2012
Venus Remedies Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended March 31, 2012. Innovative Solution for alleviating cancer
Venus Remedies Ltd has informed BSE about Innovative Solution for alleviating cancer.Announcement:"The Company has established pre-clinical proof of concept for its Drug-Protein-Polymer- Conjugate (DPPC). DPPC concept by Venus is a novel, patent protected technology, which will help in alleviating cancer specific and selective targeting of tumor cells." (For more details kindly refer Corporate Announcements on www.bseindia.com). Venus Remedies "Vancoplus" gets Patent from Australia
Venus Remedies Ltd has informed BSE that Venus Remedies "Vancoplus" gets Patent from Australia.Annouvement:"The Company has added one more patent to its kitty for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus ( MRSA ) infections. After Potentox, this is companys second patent grant from the Australian Patent office (APO), Government of Australia, and is valid till February 2026."... Venus's ACHNIL, BioSpectrum Product of the Year 2012
Venus Remedies Ltd has informed BSE regarding "Venus's ACHNIL, BioSpectrum Product of the Year 2012".Announcement:"The Company has received "BioSpectrum Product of the Year 2012" award for its novel research product 'ACHNIL', a once-a-day painkiller. The award was presented at a glittering BioSpectrum Asia Award function in Singapore on March 16, 2012." (For more details kindly refer Corporate Announcements on www.bseindia.com). Outcome of Board Meeting
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 27, 2012, inter alia, has approved allotment of 600,000 equity shares of Rs. 10 each to promoter group Company pursuant to conversion of warrants fully convertible into equity shares.